BGF invested in biotechnology company TRIMTECH Therapeutics to support progression of lead programmes into pre-clinical development.
TRIMTECH Therapeutics is a biotechnology company that is developing a targeted protein degradation platform designed to address neurodegenerative diseases by degrading toxic protein aggregates
TRIMTECH Therapeutics is a biotechnology company that is developing a targeted protein degradation platform designed to address neurodegenerative diseases by degrading toxic protein aggregates.